Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02286531 : Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

Patients over 18 years

- Diagnosis of glioma grade II referred on clinical and MRI morphologic

- Realization of a brain MRI in preoperative condition of neuronavigation (MRI
sequences including axial T2, Flair, T1, T1 with gadolinium) in a within 1 month with

- Histological examination scheduled within one month with FET PET by resection
(complete or partial) or by biopsy

- Patients who signed informed consent

- No against-indication for PET

- No against-indications to MRI

Exclusion Criteria:

- Grade II glioma who have received specific treatment with radiotherapy and or

- Pregnant or breastfeeding women.

- Weight greater than 120 Kg

- against-indication to PET

- against- indication gadolinium

- Possible side effects to MRI (magnetic foreign bodies, pacemaker, congestive severe

- Patient under guardianship

- No coverage by social security
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557